Dalton president and CEO, Peter Pekos, told Outsourcing-Pharma that Dalton’s service offerings will be enhanced, enabling the Health Canada approved contract pharmaceutical manufacturer, “to cover all aspects of the drug development spectrum.”
According to Pekos, Lonza compliments Dalton in chemistry manufacturing of molecule classes like peptides and large molecules that require aseptic filling services. In exchange, he said Dalton, with its strong presence in the US, can offer Lonza’s customers a “North American footprint.”
The firms say the aim of the agreement is to ensure every stage of a clients drug development process is ‘seamlessly’ structured to ensure speed and quality, with a focus on smooth transfers of technology at each phase, including the transition of projects to Lonza’s cGMP and ISO manufacturing sites in China or Switzerland.
Dalton claims to have seen an increase in demand for integrated services, which Pekos believes can speed up the drug development cycle, proving more efficient and less expensive for customers.
“Our clients have been asking for this full spectrum of capabilities to fill an important need in our industry,” said Pekos. “Over the past two decades I have worked to adjust [Dalton’s] service offerings to meet the changing requirements of my clients.”
Accelerating drug development
While a number of other pharmaceutical manufacturing organisations offer the same fully integrated services, Pekos said the combined firms’ competitive advantage is their commitment to accelerating customers’ drug development efforts.
Pekos hopes the collaboration will enable Dalton and Lonza to help move clients’ products quickly through critical stages to meet important milestones using the latest technology, which will lead to commercial success.
Claiming there are limited sources for drug development funding, and that Venture funds are backing more projects that require expertise at various stages of the program, Pekos said Dalton is well positioned to cater for clients lookingto outside service providers for expertise in the manufacturing space.
“These Venture-backed pharma companies, largely based in North America, appreciate rapid response to program changes in the early phases, and Dalton will continue to provide this ability,” he said.